Navigation Links
GlycoVaxyn AG secures CHF 5.1 million Strategic Translation Award from the Wellcome Trust to finance clinical development of Shigella vaccine

ZURICH-SCHLIEREN, Switzerland, July 29, 2013 /PRNewswire/ -- Following recently signed collaborations with GlaxoSmithKline Biologicals (GSK) and Janssen Pharmaceuticals (JPI), GlycoVaxyn AG, a leader in the development of innovative conjugate vaccines, today announced that it has secured a Strategic Translation Award from the Wellcome Trust to finance its Shigella program.

The award will allow the Company to advance its Shigella bioconjugate vaccine by funding human safety and challenge studies in healthy adults to confirm the efficacy of a monovalent Shigella flexneri 2a vaccine, before testing a multivalent vaccine in field studies in children. Clinical trials are scheduled to start in 2014 in the USA.

Shigella is one of the main causes of a diarrheal disease that causes illness and death among young children in low-income countries. Various serotypes of this Gram-negative bacterium are responsible for the diarrhea and, with regional differences in serotype distribution, up to 6 serotypes need to be included in a vaccine to provide broad protection and prevent Shigellosis worldwide.

GlycoVaxyn's in vivo glycosylation technology enables the possibility to develop such a complex multivalent Shigella vaccine for the first time. Complexes of the antigenic surface polysaccharides and proteins can now be directly synthesized in genetically engineered bacterial cells. This multivalent Shigella bioconjugate vaccine can be manufactured at low costs, a distinct advantage compared to conjugate vaccines that are chemically produced.

"An estimated 1.1 million people die from Shigella infections each year, mostly children under the age of five living in low income countries," said Richard Seabrook, Ph.D., head of Business Development at the Wellcome Trust. "With rising antibiotic resistance limiting our treatment options, we urgently need an affordable vaccine that will provide broad protection against the many strains of Shigella bacteria that cause disease."

Dr Michael Wacker, chief scientific officer of GlycoVaxyn added, "We are very honored to work with this prestigious global charitable foundation and proud to contribute to the development of a vaccine that addresses a critical medical need among millions around the world. GlycoVaxyn has previously conducted a Phase 1 study in healthy volunteers on a single serotype Shigella conjugate vaccine. This collaboration will enable us to investigate a new vaccine against a different single serotype, moving this important program forward towards a broad acting vaccine that protects against multiple serotypes."

Gordon Dougan, Ph.D., member of GlycoVaxyn's Scientific Advisory Board and professor at the Wellcome Trust Sanger Institute in Cambridge commented, "GlycoVaxyn is using highly innovative technology to break open new fields in vaccinology. I am delighted to see them work together with the Wellcome Trust to apply this technology to vaccines for children suffering from dysentery."

About GlycoVaxyn AGGlycoVaxyn is a privately-funded company developing a portfolio of novel bio-conjugate vaccines against common severe bacterial infections produced with its unique, proprietary in vivo glycosylation platform. With this platform, the company can develop and produce immunogenic glycoprotein conjugates in a biological process that circumvents many of the challenges and uncertainties involved in currently used chemical methods. Besides Shigella, the portfolio includes preclinical programs targeting major infectious diseases such as Staphylococcus aureus and Streptococcus pneumoniae. GlycoVaxyn is funded by a top-tier group of private investors including Sofinnova Partners, Index Ventures and Edmond de Rothschild Investment Partners and recently entered collaborations with GSK and JPI. For further information, visit

About The Wellcome TrustThe Wellcome Trust is a global charitable foundation dedicated to achieving extraordinary improvements in human and animal health. It supports the brightest minds in biomedical research and the medical humanities. The Trust's breadth of support includes public engagement, education and the application of research to improve health. It is independent of both political and commercial interests. Contacts: Robert FlammGlycoVaxyn AGRusso Partners, LLCTel: +41-44-733-8595Tel: 



SOURCE GlycoVaxyn AG
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. GlycoVaxyn AG announces Addition of Gerd Zettlmeissl, as Chairman of the Board of Directors
2. Modern Mobility Aids, Inc. Secures Financing to Close Acquisition Agreement of LumiGene Technologies
3. A New Type of Dendritic Cell-Based Cancer Vaccine has Received Approval for Clinical Tests and at the Same Time Secures Substantial Financing
4. Roka Bioscience Secures $47.5 Million in Series D Financing
5. Generex Secures Commitments for $3.6M Capital Raise
6. PharmAthene Secures $7.5 Million Credit Facility From GE Capital, Healthcare Financial Services
7. Insmed Secures $20 Million Loan Agreement With Hercules Technology Growth Capital
8. Bacterin Secures $25 Million Financing with OrbiMed
9. OncoSec Secures License for Electroporation Intellectual Property from University of South Florida
10. Aviir Diagnostic Laboratories Secures $8 Million In Funding From Silicon Valley Bank
11. Syngenta Secures EU Approval For Next Generation Fungicide
Post Your Comments:
(Date:11/24/2015)... --> --> ... by Transparency Market Research, the global non-invasive prenatal testing ... 17.5% during the period between 2014 and 2022. The ... Analysis, Size, Volume, Share, Growth, Trends and Forecast 2014 ... to reach a valuation of US$2.38 bn by 2022. ...
(Date:11/24/2015)... ... November 24, 2015 , ... In harsh industrial ... points for in-line sensors can represent a weak spot where leaking process media ... of retractable sensor housings , which are designed to tolerate extreme process conditions. ...
(Date:11/24/2015)... LOS ANGELES , Nov. 24, 2015 ... a biotechnology company focused on the discovery, development and ... Marban , Ph.D., Chief Executive Officer, is scheduled to ... December 1, 2015 at 10:50 a.m. EST, at The ... York City . . ...
(Date:11/24/2015)... ... , ... Whitehouse Laboratories is pleased to announce that it has completed construction ... dedicated to basic USP 61, USP 62 and USP 51 testing specific to raw ... and micro testing performed by one supplier. Management has formally announced that ...
Breaking Biology Technology:
(Date:11/9/2015)... 09, 2015 ... the "Global Law Enforcement Biometrics Market ... --> ) has announced the ... Biometrics Market 2015-2019" report to their ... ( ) has announced the addition ...
(Date:10/29/2015)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, is pleased to announce that it has been ... one of only three finalists for a 2015 ... Growing" category. The Tekne Awards honor Minnesota ... innovation and leadership. iMedNet™ eClinical ...
(Date:10/29/2015)... Oct. 29, 2015  Connected health pioneer, Joseph ... explosion of technology-enabled health and wellness, and the business ... The Internet of Healthy Things . ... smartphones even existed, Dr. Kvedar, vice president, Connected Health, ... care delivery, moving care from the hospital or doctor,s ...
Breaking Biology News(10 mins):